| Sep 28 |
Jim Cramer on Regeneron Pharmaceuticals Inc. (REGN): ‘Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Biosimilar Preliminary Injunction Ruling’
|
| Sep 27 |
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
|
| Sep 27 |
Regeneron Shares Head for Worst Month Since 2019 on Legal Ruling
|
| Sep 27 |
FDA greenlights Regeneron’s Dupixent for the treatment of COPD
|
| Sep 27 |
Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD
|
| Sep 27 |
Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval
|
| Sep 27 |
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
|
| Sep 27 |
Sanofi, Regeneron get additional Chinese approval for Dupixent
|
| Sep 27 |
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
|
| Sep 27 |
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
|
